{"id":714,"date":"2021-04-13T11:46:55","date_gmt":"2021-04-13T11:46:55","guid":{"rendered":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=714"},"modified":"2021-04-13T11:46:55","modified_gmt":"2021-04-13T11:46:55","slug":"nota-informativa-muh-fv-05-2021","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2021\/04\/13\/nota-informativa-muh-fv-05-2021\/","title":{"rendered":"Nota Informativa MUH (FV), 05\/2021"},"content":{"rendered":"<p><a href=\"https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/2021-seguridad-1\/esmya-acetato-de-ulipristal-5-mg-levantamiento-de-la-suspension-de-comercializacion-con-restricciones-en-sus-indicaciones-debido-al-riesgo-de-dano-hepatico-grave\/\">Esmya (acetato de ulipristal 5 mg): levantamiento de la suspensi\u00f3n de comercializaci\u00f3n, con restricciones en sus indicaciones debido al riesgo de da\u00f1o hep\u00e1tico grave<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Esmya (acetato de ulipristal 5 mg): levantamiento de la suspensi\u00f3n de comercializaci\u00f3n, con restricciones en sus indicaciones debido al riesgo de da\u00f1o hep\u00e1tico grave<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-714","post","type-post","status-publish","format-standard","hentry","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=714"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/714\/revisions"}],"predecessor-version":[{"id":715,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/714\/revisions\/715"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}